NYSEMKT: MTNBMatinas Biopharma Holdings Inc Stock
$0.18-0.01 (-5.26%)
Updated Apr 22, 2024
MTNB Price
$0.18
Fair Value Price
N/A
Market Cap
$39.15M
52 Week Low
$0.11
52 Week High
$0.89
P/E
-1.64x
P/B
2.03x
P/S
42.86x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.10M
Earnings
-$22.94M
Gross Margin
100%
Operating Margin
-2,093.25%
Profit Margin
-2,093.2%
Debt to Equity
0.3
Operating Cash Flow
-$15M
Beta
1.07
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MTNB Overview
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company is headquartered in Bedminster, New Jersey and currently employs 15 full-time employees. The firm focuses on identifying and developing novel pharmaceutical products. The firm's technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, which is designed to make safer, more tolerable, less toxic and orally bioavailable. The firm's technology combines the use of lipids as active pharmaceutical ingredients (APIs) and the use of lipids in cochleate-shaped lipid-crystal nano-particle drug delivery vehicles. The Company’s product candidates include, MAT2203 and MAT2501.The Company's anti-infective product candidate, MAT 2203, is an application of its cochleate delivery technology to a spectrum anti-fungal drug called amphotericin B. The firm's MAT2501 is an orally administered, encochleated formulation of the spectrum IV-only aminoglycoside antibiotic agent amikacin, utilizes the Company's lipid-crystal, nanoparticle delivery technology.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MTNB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MTNB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MTNB is good value based on its book value relative to its share price (2.03x), compared to the US Biotechnology industry average (5.82x)
P/B vs Industry Valuation
MTNB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MTNB due diligence checks available for Premium users.
Be the first to know about important MTNB news, forecast changes, insider trades & much more!
MTNB News
Valuation
MTNB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.64x
Industry
16.21x
Market
41x
MTNB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.03x
Industry
5.82x
MTNB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MTNB's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.3M
Profit Margin
0%
MTNB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MTNB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$25.1M
Liabilities
$5.9M
Debt to equity
0.3
MTNB's short-term assets ($15.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MTNB's short-term assets ($15.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MTNB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MTNB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.6M
Investing
$3.0M
Financing
-$1.0k
MTNB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MTNB vs Biotech Stocks
Matinas Biopharma Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.